Alnylam Pharmaceuticals (ALNY) could have an edge on Ionis Pharmaceuticals (IONS) in treating a rare disease that results in organ and system damage, an analyst said Monday.
Over the weekend, Ionis presented data from a Phase 3 trial showing its drug, inotersen, improved quality of life in TTR amyloidosis patients over 15 months vs. a placebo. In these patients, tissues called amyloid build up, causing damage to organs and systems.
